Alexander Laird

10.0k total citations · 4 hit papers
97 papers, 4.9k citations indexed

About

Alexander Laird is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alexander Laird has authored 97 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 41 papers in Oncology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alexander Laird's work include Renal cell carcinoma treatment (19 papers), Renal and related cancers (16 papers) and PI3K/AKT/mTOR signaling in cancer (14 papers). Alexander Laird is often cited by papers focused on Renal cell carcinoma treatment (19 papers), Renal and related cancers (16 papers) and PI3K/AKT/mTOR signaling in cancer (14 papers). Alexander Laird collaborates with scholars based in United States, United Kingdom and Germany. Alexander Laird's co-authors include N Fausto, Eric M. Webber, Julie M. Cherrington, Dirk B. Mendel, Belinda Cancilla, Frauke Bentzien, Alison Joly, Peiwen Yu, Yu-Chien Chou and Justin Lesch and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Alexander Laird

93 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

2011 1.0k citations F. Michael Yakes, Jason Chen et al. Molecular Cancer Therapeutics profile →
Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration.

1995 521 citations Alexander Laird et al. profile →
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

2018 354 citations Jörge E. Cortes, Daniel A. Pollyea et al. profile →
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

2021 183 citations Johann S. de Bono, Giorgio V. Scagliotti et al. profile →

Peers

Countries citing papers authored by Alexander Laird

Since Specialization

Citations

This map shows the geographic impact of Alexander Laird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Laird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Laird more than expected).

Fields of papers citing papers by Alexander Laird

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Laird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Laird. The network helps show where Alexander Laird may publish in the future.

Co-authorship network of co-authors of Alexander Laird

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Laird. A scholar is included among the top collaborators of Alexander Laird based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Laird. Alexander Laird is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Malignant upper urinary tract obstruction in cancer patients: A systematic review 2024 ·SHILAP Revista de lepidopterología ·Max Shah, (unknown), James P. Blackmur, Alexander Laird, Shoba Dawson, Jonathan Aning	1
2	DESI-MSI-guided exploration of metabolic-phenotypic relationships reveals a correlation between PI 38:3 and proliferating cells in clear cell renal cell carcinoma via single-section co-registration of multimodal imaging 2024 ·Analytical and Bioanalytical Chemistry ·(unknown), In Hwa Um, Alexander Laird, David J. Harrison, (unknown)	7
3	Single-cell analysis of senescent epithelia reveals targetable mechanisms promoting fibrosis 2022 ·JCI Insight ·Eoin O’Sullivan, Katie J. Mylonas, Rachel Bell, (unknown), David Baird, Carolynn Cairns, Kevin Gallagher, (unknown), (unknown), Alexander Laird, Neil C. Henderson, Tamir Chandra, Kristina Kirschner, Bryan R. Conway, Gry H. Dihazi, Michael Zeisberg, Jeremy Hughes, Laura Denby, Hassan Dihazi, David A. Ferenbach	21
4	Real world outcomes of biopsy‐proven oncocytic neoplasm of the kidney managed by surveillance 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), James A. Armitage, Anne Y. Warren, Jane Hendry, Grant D. Stewart, Alexander Laird, Grenville Oades	4
5	Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy? 2022 ·British Journal of Urology ·Matthew Trail, (unknown), (unknown), James P. Blackmur, Abhishek Sharma, (unknown), Marie O’Donnell, (unknown), J Brush, John Taylor, Simon Phipps, Ben Thomas, (unknown), S. Alan McNeill, (unknown), Mark L. Cutress, Alexander Laird	4
6	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 2021 ·Clinical Cancer Research ·Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan O’Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin T. Nguyen, Barbara Sleight, Erik Vandendries, (unknown), Alexander Laird, Anjali S. Advani	29
7	580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity 2021 ·Annals of Oncology ·(unknown), Johann S. de Bono, Alexander Laird, Philippe Barthélémy, R. Delva, Tanya B. Dorff, Marco Maruzzo, A. Stirling, J-P. Machiels, Herlinde Dumez, Vincent Renard, Julia F. Hopkins, Lee A. Albacker, Hsiang‐Cheng Chen, Cynthia G. Healy, Jijumon Chelliserry, Inge M. van Oort, Giorgio V. Scagliotti, Karim Fizazi	1
8	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial 2019 ·Leukemia Research ·(unknown), Nicola Gökbuget, Anjali S. Advani, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Giovanni Martinelli, Susan O’Brien, Tao Wang, Alexander Laird, Erik Vandendries, (unknown), Kevin T. Nguyen, Naveen Dakappagari, Daniel J. DeAngelo, Hagop Kantarjian	37
9	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS 2018 ·Clinical Cancer Research ·Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey E. Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy, M. Naveed Shaik, Alexander Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jörge E. Cortes	86
10	Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status 2017 ·Blood ·Anjali S. Advani, Elias Jabbour, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Nicola Goekbuget, Susan O’Brien, Jane Liang White, Tao Wang, Alexander Laird, Erik Vandendries, Hagop M. Kantarjian	2
11	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer 2015 ·Clinical Cancer Research ·Grant D. Stewart, Fiach C. O’Mahony, Alexander Laird, Lél Eöry, (unknown), Alan Mackay, Jyoti Nanda, Marie O’Donnell, Peter Mullen, S. Alan McNeill, Antony C. P. Riddick, Daniel M. Berney, Axel Bex, Michael Aitchison, Ian M. Overton, David J. Harrison, Thomas Powles	29
12	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Égile, Rodrigo Ruiz-Soto, Alexander Laird, Dale Miles, Patricia LoRusso	87
13	Contemporary practice and technique‐related outcomes for radical prostatectomy in the UK : a report of national outcomes 2014 ·British Journal of Urology ·Alexander Laird, Sarah Fowler, Daniel W. Good, Grant D. Stewart, (unknown), Declan Cahill, Simon Brewster, S. Alan McNeill	19
14	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, Alexander Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. Edelman	123
15	Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. 2012 ·Journal of Clinical Oncology ·Grant D. Stewart, Fiach C. O’Mahony, Lél Eöry, Jyoti Nanda, Alexander Laird, Marie O’Donnell, Peter Mullen, Antony C. P. Riddick, Alan McNeill, Michael Aitchison, Daniel M. Berney, John Peters, Andrea Rockall, Anju Sahdev, Axel Bex, Dana Faratian, Simon Chowdhury, David J. Harrison, Ian M. Overton, Thomas Powles	2
16	Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth breakdown → 2011 ·Molecular Cancer Therapeutics ·F. Michael Yakes, Jason Chen, Jenny Tan, Toshihiro Yamaguchi, Yongchang Shi, Peiwen Yu, Fawn Qian, Felix Chu, Frauke Bentzien, Belinda Cancilla, Jessica Orf, Andrew You, Alexander Laird, Stefan Engst, Lillian Lee, Justin Lesch, Yu-Chien Chou, Alison Joly	1036
17	Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor 2007 ·Molecular Cancer Therapeutics ·Geoffrey I. Shapiro, Gerald M. Edelman, Emiliano Calvo, Sanjay Aggarwal, Alexander Laird	14
18	XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR 2007 ·Molecular Cancer Therapeutics ·Alexander Laird	14
19	Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a Phase I clinical trial 2007 ·Molecular Cancer Therapeutics ·Amita Patnaik, Patricia LoRusso, Josep Tabernero, Alexander Laird, Sanjay Aggarwal, Kyriakos P. Papadopoulos	8
20	Oncoprotein Signalling and Mitosis 1997 ·Cellular Signalling ·Alexander Laird, David Shalloway	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact